8-K: Aspire Biopharma Stockholders Approve Reverse Split, Note Issuance

Aspire Biopharma Holdings' stockholders approved a potential reverse stock split and the issuance of shares for convertible promissory notes at a special meeting.

Summary

• Stockholders of Aspire Biopharma Holdings, Inc. (ASBP) held a Special Meeting on November 4, 2025, to vote on two key proposals.
• The Reverse Stock Split Proposal was approved, granting the Board of Directors discretionary authority to amend the Certificate of Incorporation to effect a reverse stock split of common stock by a ratio of one-for-five (1-for-5) to one-for-forty (1-for-40).
• The Board has one year from the approval date to effect the reverse stock split, if at all.
• Voting results for the Reverse Stock Split Proposal were: 24,965,481 For, 5,988,513 Against, and 29,704 Abstain.
• The Notes Proposal was also approved, allowing the issuance of more than 19.99% of outstanding common stock upon exercise of certain Convertible Promissory Notes (Notes) issued pursuant to agreements dated August 19, 2025.
• The approval also set the floor price for conversion of the Notes at 20% of the average closing price of common stock for the five days prior to the Closing Date.
• Voting results for the Notes Proposal were: 19,852,827 For, 3,747,867 Against, 8,577 Abstain, and 7,374,427 Broker Non-Votes.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative. While securing financing and addressing potential Nasdaq compliance issues are necessary steps, the need for a reverse stock split and the significant potential dilution from convertible notes at a low floor price suggest underlying challenges for the company and potential adverse impacts on existing shareholders.

Positives

• Stockholder approval for the reverse stock split provides the company with a mechanism to potentially meet Nasdaq listing requirements, which often have minimum bid price thresholds.
• Approval of the Notes Proposal facilitates the issuance of shares for Convertible Promissory Notes, indicating successful capital raising efforts to support company operations and strategic initiatives.

Negatives

• The need for a reverse stock split often signals a significantly low share price, which can be perceived negatively by the market and may not guarantee a sustained price increase.
• The issuance of more than 19.99% of outstanding common stock upon conversion of the Notes represents significant potential dilution for existing shareholders.
• A conversion floor price set at 20% of the average closing price suggests that the convertible notes could be converted at a very low price relative to current market value, exacerbating dilution.

Risks

• A reverse stock split does not guarantee a sustained increase in share price and may not improve market liquidity or investor confidence.
• Significant dilution from the conversion of Convertible Promissory Notes could negatively impact the value of existing shareholders' investments.
• The low floor price for note conversion (20% of the 5-day average closing price) increases the risk of substantial dilution at potentially unfavorable terms for current equity holders.

Future Outlook

The Board of Directors has discretionary authority to effect a reverse stock split within one year of the November 4, 2025 approval date. The company anticipates the potential conversion of Convertible Promissory Notes into common stock, subject to the approved floor price.

Management Comments

• Kraig Higginson, Chief Executive Officer, signed the report on behalf of Aspire Biopharma Holdings, Inc.

Industry Context

Biopharma companies often require significant capital for research, development, and operations, making convertible notes a common financing tool. Reverse stock splits are frequently utilized by companies, particularly in the biotech sector, to maintain compliance with exchange listing standards (e.g., Nasdaq's minimum bid price rule) when their stock price has fallen significantly.

Corporate Governance

Stakeholder Impact

• Shareholders will be directly impacted by the reverse stock split, which will reduce the number of outstanding shares and proportionally increase the per-share price, without changing the total value of their holdings immediately.
• Existing shareholders face potential significant dilution from the conversion of the Convertible Promissory Notes, as more than 19.99% of outstanding shares could be issued, potentially at a low floor price.
• The capital raise through convertible notes provides funding for the company, which could benefit employees, suppliers, and creditors by ensuring continued operations and financial stability.

Next Steps

• The Board of Directors will determine, in its sole discretion, whether and when to effect the approved reverse stock split within one year of November 4, 2025.
• The Convertible Promissory Notes are expected to be convertible into common stock based on the approved terms, including the floor price.

Key Dates

Recommendation

The approval of a reverse stock split and a dilutive capital raise through convertible notes presents a mixed signal. While these actions address immediate concerns like Nasdaq compliance and funding, they also highlight underlying challenges and significant potential dilution for existing shareholders. A 'hold' recommendation is appropriate for existing investors to observe the execution of these plans and their actual impact on the company's financial health and market valuation before making further investment decisions. For new investors, more comprehensive financial data would be required.

Keywords

Reverse Stock Split, Convertible Promissory Notes, Stockholder Vote, Nasdaq Compliance, Dilution, Capital Raise, Biopharma, ASBP